Dr. Emily Teslow will discuss MSI testing gold standards and compare the different methods that are currently being used for microsatellite instability (MSI) testing for mismatch repair deficient (dMMR) tumors. Then she will discuss the clinical relevance of the MSI-H biomarker focusing on the pathological and epidemiological characteristics of MSI-H/dMMR tumors, and the role of MSI testing in Lynch syndrome screening, colorectal cancer patient prognosis, and immunotherapy treatment.

Learning objectives

• Compare techniques used to measure microsatellite instability to current gold-standard methods
• Discuss the clinical utility of the MSI biomarker for Lynch syndrome screening and immunotherapy treatment
• Review the most current clinical practice guidelines for MSI testing